Cannabis Law and Access in Ireland

Ireland's cannabis laws: a closer look from the outside

Forty-seven countries now have some form of medical cannabis programme on the books. Ireland joined that count in 2019, and if you read the headline you'd think it was a reasonably straightforward step. It wasn't , and honestly it still isn't. The Irish framework is among the more restrictive medical access systems in the EU, and the gap between what the law technically permits and what patients can actually access in practice is wide enough to drive a lorry through.

A quick note before we go any further: this article describes Irish law. It is not Australian law. Australian readers seeking information on domestic cannabis access should look at the TGA's pathways , including the Special Access Scheme and the Authorised Prescriber framework , which operate under entirely different legislation and scheduling rules.

The legal foundation: Misuse of Drugs Act and the Poisons Regulations

Cannabis in Ireland is primarily governed by the Misuse of Drugs Act 1977 (as amended) and associated Misuse of Drugs Regulations. Under that framework, cannabis is a Schedule 1 controlled drug; meaning possession, supply, and cultivation are criminal offences for most people. There is no decriminalisation of personal possession at the statute level, though prosecutorial discretion does exist and a 2023 Citizens' Assembly recommended a significant shift toward decriminalisation. As of mid-2025, those recommendations have not been enacted into legislation.

A Drugs Policy Minister was appointed in 2020 following years of advocacy, and a National Drugs Strategy has been in place since 2017. But strategy documents and legislative change are two very different things, and Ireland's statute books still treat cannabis possession as a criminal matter.

The Medical Cannabis Access Programme (MCAP)

The Medical Cannabis Access Programme, known as MCAP, was established under SI 262 of 2019, the Misuse of Drugs (Amendment) Regulations. It sits as a formal carve-out from the prohibition regime, allowing a narrow class of patients to access cannabis-based products through a defined approval process.

MCAP is not a broad medical cannabis scheme. It is deliberately limited. Access is confined to patients with specific conditions: spasticity associated with multiple sclerosis, intractable nausea and vomiting associated with chemotherapy, and severe, refractory (treatment-resistant) epilepsy. That last category has attracted the most clinical attention. Specialist medical practitioners; not GPs, must apply to the Minister for Health on behalf of each patient. The Minister grants (or refuses) access on a case-by-case basis. Products must be manufactured to pharmaceutical-grade standards.

The products available under MCAP must be authorised and meet quality and safety standards set by the Health Products Regulatory Authority (HPRA), Ireland's equivalent of the TGA. Good Manufacturing Practice is a hard requirement; ad hoc or artisanal products do not qualify. This is worth emphasising because it matters for what kinds of preparations are actually on the approved list, and that list has remained short.

What's actually on the approved list

As of 2025, the number of products that have cleared the HPRA process and are available under MCAP is small. Products containing THC, CBD, or a combination of both have been evaluated, but the process is slow and the pathway has been criticised by patient advocacy groups for creating a bottleneck.

Cannabidiol-only products that fall below the threshold for medicinal classification sit in a separate, greyer zone. In Ireland, as in most EU member states, the European Court of Justice's 2020 Kanavape ruling; which found that CBD derived from the whole cannabis plant could not be classified as a narcotic under EU law, has had flow-on effects on how low-THC, CBD-dominant products are treated in the market. But "not a narcotic" does not automatically mean "freely available," and HPRA oversight of health claims and novel food classification under EU food law creates its own set of constraints.

Industrial hemp and the agricultural side

Hemp cultivation, cannabis varieties with THC content at or below 0.2%; is legal in Ireland under EU agricultural regulations, provided growers hold a licence from the Department of Agriculture, Food and the Marine. The EU approved varieties list governs which cultivars can be grown. This sits entirely separately from the medicinal regime; hemp fibre, seed, and certain food products can move in commerce, but extracting and selling CBD from those crops as a consumable health product runs straight into HPRA oversight and EU novel food rules.

It's a regulatory maze, and I'll admit I find it genuinely interesting from a comparative law perspective. The Australian system has its own complications, the ARTG listing process, the distinction between Schedule 4 and Schedule 8 controlled substances, but at least the TGA has published reasonably clear guidance documents. The Irish equivalent literature is more scattered.

Possession, enforcement, and the decriminalisation debate

For cannabis outside the MCAP; so, the vast majority of cannabis in circulation, possession remains a criminal offence. The Garda (Irish police) exercise prosecutorial discretion, particularly for small amounts, but this is not codified. A caution regime for simple possession has operated in practice, but it is not a formal legal protection.

The 2023 Citizens' Assembly on Drugs Use, convened by the Oireachtas, recommended decriminalising possession of cannabis and other drugs for personal use and investing in health-based responses. The Assembly's report is on record; it does not have the force of law. The government's response has been cautious, and no decriminalisation legislation had passed as of mid-2025. This is a live political debate, not a settled one.

In my view, the gap between the Citizens' Assembly's recommendations and actual legislative movement represents a familiar policy drag, politically sensitive reform stalls in committee while the underlying enforcement issues continue on the ground. That's not unique to Ireland, but it does mean the headline "Ireland considering decriminalisation" needs to be read carefully alongside what the statute actually says today.

How Ireland compares in the EU context

Several EU member states have moved further than Ireland on cannabis access. Germany's 2024 Cannabis Act (CanG) introduced a limited legalisation of recreational possession and non-commercial cultivation for adults, plus an expansion of medical access. The Netherlands has operated a tolerated retail market for decades. Portugal decriminalised personal possession of all drugs in 2001; though production and supply remain criminal offences.

Ireland sits closer to the cautious end of the EU spectrum. Given that EU member states retain sovereignty over drug scheduling domestically (narcotics policy is not harmonised at EU level), the variation across the bloc is significant. For anyone researching this area, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) publishes country drug reports annually and is the most reliable comparative source.

From a pharmacology standpoint, the same cannabinoid science underlies every jurisdiction's debate. The endocannabinoid system doesn't care about borders. But how any given country schedules, permits, and regulates access to compounds like CBD and THC is a policy question, not a biochemistry question. Those two things get conflated more often than they should.

What Australian readers should take from this

If you're in Australia and you've landed here because you're curious about how cannabis law works internationally, fair enough, it's a fast-moving area and the comparisons are genuinely useful for understanding where Australia sits. But nothing in Irish law affects what's available or accessible in Australia. The TGA's scheduling decisions, the SAS Category pathways, and the Authorised Prescriber scheme are the relevant instruments here, and they operate independently of what Ireland, Germany, or anyone else is doing.

I spent last weekend on a long road ride out past Bungendore, good country for thinking; and found myself turning over the Citizens' Assembly question. Deliberative democracy processes are fascinating instruments. Whether they translate into statute is another matter entirely. Same dynamic plays out in every jurisdiction wrestling with cannabis reform, including this one.

The short version is: Ireland has a narrow, specialist-only medical cannabis access programme, cannabis possession remains a criminal offence under statute, and meaningful decriminalisation reform is in political discussion but not yet law. Watch the Oireachtas, not the headlines.

Sources

• Cannabis-Based Products, Health Products Regulatory Authority (HPRA)
• Ireland Drug Report 2024, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
• Report of the Citizens' Assembly on Drugs Use; Government of Ireland
• Medicinal Cannabis, Guidance for Patients, Therapeutic Goods Administration (TGA)

, Marcus Hale, Regulatory researcher; TGA & access law